- Home
- CAPR vs FRBA Comparison
CAPR vs FRBA Comparison
Compare CAPR & FRBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- FRBA
- Stock Information
- Founded
- CAPR 2005
- FRBA 2007
- Country
- CAPR United States
- FRBA United States
- Employees
- CAPR N/A
- FRBA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- FRBA Major Banks
- Sector
- CAPR Health Care
- FRBA Finance
- Exchange
- CAPR Nasdaq
- FRBA Nasdaq
- Market Cap
- CAPR 322.7M
- FRBA 363.6M
- IPO Year
- CAPR N/A
- FRBA N/A
- Fundamental
- Price
- CAPR $8.43
- FRBA $15.22
- Analyst Decision
- CAPR Strong Buy
- FRBA Strong Buy
- Analyst Count
- CAPR 8
- FRBA 2
- Target Price
- CAPR $24.75
- FRBA $18.00
- AVG Volume (30 Days)
- CAPR 2.7M
- FRBA 43.1K
- Earning Date
- CAPR 08-06-2025
- FRBA 07-22-2025
- Dividend Yield
- CAPR N/A
- FRBA 1.59%
- EPS Growth
- CAPR N/A
- FRBA 22.16
- EPS
- CAPR N/A
- FRBA 1.51
- Revenue
- CAPR $17,363,588.00
- FRBA $131,202,000.00
- Revenue This Year
- CAPR $453.92
- FRBA $5.46
- Revenue Next Year
- CAPR N/A
- FRBA $6.18
- P/E Ratio
- CAPR N/A
- FRBA $10.00
- Revenue Growth
- CAPR N/A
- FRBA 14.51
- 52 Week Low
- CAPR $3.52
- FRBA $12.74
- 52 Week High
- CAPR $23.40
- FRBA $16.47
- Technical
- Relative Strength Index (RSI)
- CAPR 38.63
- FRBA 43.18
- Support Level
- CAPR $6.26
- FRBA $14.85
- Resistance Level
- CAPR $7.28
- FRBA $15.35
- Average True Range (ATR)
- CAPR 0.69
- FRBA 0.37
- MACD
- CAPR -0.04
- FRBA -0.10
- Stochastic Oscillator
- CAPR 10.28
- FRBA 21.01
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.